Maren Thurow starts as new Head Global Communications at Grünenthal
Maren Thurow has today assumed the role of Vice President and Head Global Communications at Grünenthal. She succeeds Florian Dieckmann, who has played a key role in evolving the company's Communications department since 2021. In her new position, Maren will oversee Grünenthal's communications operations across all markets and lead the team based at the company's headquarters in Aachen. She will report directly to CEO Gabriel Baertschi.
This appointment comes at a pivotal moment in Grünenthal's transformation, following the company's outstanding financial performance in 2024. Since 2017, Grünenthal's profitability, measured by adjusted EBITDA, has more than tripled, driven by strategic acquisitions and partnerships such as the acquisition of the US company Valinor Pharma and the product Movantik™ in July 2024. Additionally, Grünenthal continues to advance its key R&D programs, including progressing the Glucocorticoid Receptor Modulator (GRM) and Nociceptin (NOP) Receptor Agonist programs to the next development stages, along with ongoing progress in its Nav compounds. The company is also focusing on accelerating growth in Qutenza™ and its Established Brands, while ensuring a smooth integration of Valinor Pharma and pursuing further strategic acquisitions.
Maren joined Grünenthal in 2021 as Head of Global Commercial Communication and was subsequently the Planning Director for the company's commercial organization. Prior to joining Grünenthal Maren was a Director at FleishmanHillard, one of the world's leading global PR firms.
About Grünenthal
Grünenthal is a global leader in pain management and related diseases. As a science-based, fully integrated pharmaceutical company, we have a long track record of bringing innovative treatments and state-of-the-art technologies to patients worldwide. Our purpose is to change lives for the better – and innovation is our passion. We focus all our activities and efforts on working towards our vision of a World Free of Pain.
Grünenthal is headquartered in Aachen, Germany, and has affiliates in 28 countries across Europe, Latin America, and the U.S. Our products are available in approx. 100 countries. In 2024, Grünenthal employed around 4,300 people and achieved revenues of €1.8 billion.
More information:https://www.grunenthal.com
Follow us on: LinkedIn:Grunenthal Group
Instagram:grunenthal
Click here for ourGrünenthal Report 2024/2025
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
35 minutes ago
- Business Wire
Fujifilm Announces First U.S. Installation of FUJIFILM REVORIA PRESS EC2100S and Additional Inline Finishing Solutions at Dynagraphics
BUSINESS WIRE)--FUJIFILM North America Corporation, Business Innovation Division, today announced the first installation of its cutting-edge FUJIFILM REVORIA PRESS™ EC2100S (EC2100S) at Dynagraphics, Inc., a family-owned and operated printing company based in Decatur, Illinois. This landmark installation, combined with a full suite of products and solutions, represents a key milestone for Fujifilm's innovative digital press technology in the U.S. market and marks a new era of enhanced productivity, exceptional print quality, and expanded service offerings for Dynagraphics. "The first installation of the EC2100S at Dynagraphics is a momentous occasion for Fujifilm," said Yuji Oki, general manager, FUJIFILM North America Corporation, Business Innovation Division. "It proves that the next generation technology we're bringing matters and is much needed. As an early adopter of our technology, we are thrilled Dynagraphics recognized and felt confident in the value our innovations will bring to their business and customers." After a full audit of the competitive field, Dynagraphics made the investment in a suite of Fujifilm products, including newly available finishing solutions from longtime partners GBC and Plockmatic, given their impressive advancements, capabilities and overall future-ready printing solutions. This included the EC2100S, complemented with a powerful Fiery ® EC21 digital front end (DFE) to deliver streamlined productivity and advanced automation, and the GBC ® FuturoPunch Pro, allowing for automated punching, along with the flagship FUJIFILM REVORIA PRESS TM PC1120 (PC1120) and an accompanying Plockmatic Booklet Maker BK450e, which significantly enhances booklet production capabilities. "We were blown away with how Fujifilm's new technology opened up a whole new realm of possibilities for digital printing,' stated Dan Niebrugge, general manager, Dynagraphics. 'From the unlimited possibilities made available with the addition of a 5th and 6th color station to upgraded toner capabilities and fuser roll advancements, moving forward with the EC2100S and PC1120 were no-brainers as we continue to evolve and expand capabilities for our customers. There is truly nothing else like them on the market. We are thrilled to have a partner like Fujifilm who is as committed to the future of printing as we are." The EC2100S, engineered for high-speed, high-quality output, is designed to enable print providers like Dynagraphics to meet the growing demands of their diverse customer base with faster turnaround times and stunning image reproduction. Key features of the EC2100S include its compact size, achieved through Fujifilm's Vertical Toner Development Technology, and its ability to deliver high image quality printing, similar to the PC1120. The integration with a Fiery DFE provides advanced color management, workflow automation, and job processing capabilities, further streamlining operations and ensuring consistent, accurate results. The installation of the EC2100S, PC1120 and the inline finishing solutions were completed at the end of April and are now fully operational. About Fujifilm FUJIFILM North America Corporation, a marketing subsidiary of FUJIFILM Holdings America Corporation, consists of six operating divisions. The Imaging Division provides consumer and commercial photographic products and services, including silver halide consumables; inkjet consumables; digital printing equipment, along with service and support; personalized photo products fulfillment; film; one-time-use cameras; and the popular INSTAX™ line of instant cameras, smartphone printers, instant film, and accessories. The Electronic Imaging Division markets its GFX System and X Series lines of mirrorless digital cameras, lenses, and accessories to provide a variety of content creation solutions for both still and moving imagery. The Optical Devices Division provides optical lenses for the broadcast, cinematography, closed circuit television, videography, and industrial markets, and also markets binoculars and other optical imaging solutions. The Business Innovation Division offers a full lineup of digital print and toner technologies focused on enabling the digital transformation of businesses and print shops with its offerings of multifunction printers, digital inkjet presses, production toner printers, software, and more. The Industrial Products Division delivers new products derived from Fujifilm technologies including data storage tape products, including OEM and FUJIFILM Ultrium LTO cartridges, desalination solutions, microfilters and gas separation membranes. For more information, please visit go to to follow Fujifilm on X, or go to to Like Fujifilm on Facebook. FUJIFILM Corporation is a subsidiary of FUJIFILM Holdings Corporation. FUJIFILM Holdings Corporation, headquartered in Tokyo, leverages its depth of knowledge and proprietary core technologies to deliver innovative products and services across the globe through the four key business segments of healthcare, electronics, business innovation, and imaging with over 70,000 employees. Guided and united by our Group Purpose of 'giving our world more smiles,' we address social challenges and create a positive impact on society through our products, services, and business operations. Under its medium-term management plan, VISION2030, which ends in FY2030, we aspire to continue our evolution into a company that creates value and smiles for various stakeholders as a collection of global leading businesses and achieve a global revenue of 4 trillion yen (29 billion USD at an exchange rate of 140 JPY/USD). For more information, please visit: For further details about our commitment to sustainability and Fujifilm's Sustainable Value Plan 2030, click here. About Dynagraphics Dynagraphics, Inc. ( is a family‑owned print and graphics firm based in Decatur, IL, specializing in large‑format, offset, digital, screen, and variable‑data printing, along with vehicle wraps, environmental graphics, bindery, and seamless storefront ordering solutions. With an unwavering commitment to exceptional quality and personalized service, Dynagraphics helps businesses of all sizes build their brands, sell merchandise, and communicate effectively. FUJIFILM and REVORIA PRESS are trademarks of FUJIFILM Corporation and its affiliates. © 2025 FUJIFILM North America Corporation and its affiliates. All rights reserved.
Business Wire
36 minutes ago
- Business Wire
Debiopharm and Alkyon Therapeutics Announce Research Collaboration to Advance the Next Generation of Radioligand Therapies
MARTIGNY, Switzerland & LAUSANNE, Switzerland & SAN DIEGO--(BUSINESS WIRE)--Debiopharm ( a privately-owned Swiss biopharmaceutical company committed to establishing tomorrow's standard of care to cure cancer and infectious diseases and Alkyon Therapeutics, Inc., a biotechnology company pioneering precision-targeted therapies, today announced the signing of a co-research agreement to evaluate the feasibility of developing targeted radioligand therapies (RLTs) using Debiopharm's proprietary AbYlink™ conjugation technology for Alkyon's modular antibody platform directed against undisclosed tumor-associated antigens. This collaboration marks a promising step toward a new generation of RLTs designed to deliver potent radiation targeted directly to cancer cells while minimizing damage to healthy tissues. By leveraging the unique strengths of both platforms, the goal is to create more effective, better-tolerated cancer treatments that improve patient quality of life and expand therapeutic options for difficult-to-treat tumors. AbYLink™ technology enables regio-selective lysine conjugation, ensuring the radioligand avoids the target binding site and facilitating streamlined, consistent manufacturing. 'We're intrigued to explore the potential of applying AbYlink™ conjugation technology to the radio-oncology field,' expressed Frederic Levy, Chief Scientific Officer, Debiopharm. 'Leveraging our innovative conjugation platform with Alkyon's engineered antibody scaffolds could open new possibilities for next-generation radiopharmaceuticals with enhanced precision and therapeutic impact.' 'This collaboration reflects our shared commitment to expanding the potential of radioligand therapies,' said Benjamin Titz, Co-Founder and CEO of Alkyon Therapeutics. 'By applying AbYlink™ to our specialized antibody scaffolds and targeting strategies tailored to the unique architecture of solid tumors, we aim to unlock new therapeutic possibilities and advance care for patients with difficult-to-treat solid tumors.' About AbYlink™ AbYlink™ is a versatile and rapid regio-selective chemical conjugation technology for use in preparing diagnostic or therapeutic conjugates. This one-step method results in stable conjugation at defined and invariable sites on the Fc domain of an antibody or the like, with no impact on antigen-binding regions. It enables a seamless and reproducible conjugation of payloads (e.g., a chelator for radiolabeling, a fluorescent dye or a drug) to antibodies or ADCs. The universal applicability of the technology has been demonstrated for various antibody isotypes and payloads. About Alkyon Therapeutics, Inc. Alkyon Therapeutics, Inc. (AlkyonTx™) is a biotechnology company developing next-generation radioligand therapies (RLTs) for solid tumors. By combining precision-engineered antibodies with advanced radiochemistry and dosimetry technologies, Alkyon aims to overcome barriers such as immune exclusion and drug resistance in difficult-to-treat cancers. Its modular platform supports monotherapies, bispecifics, and rational combinations designed to enable differentiated clinical benefit and scalable product development. Debiopharm's commitment to patients Debiopharm aims to develop innovative therapies that target high unmet medical needs primarily in oncology and bacterial infections. Bridging the gap between disruptive discovery products and real-world patient reach, we identify high-potential compounds and technologies for in-licensing, clinically demonstrate their safety and efficacy, and then hand stewardship to large pharmaceutical commercialization partners to maximize patient access globally. For more information, please visit
Yahoo
an hour ago
- Yahoo
RHINOSHIELD Launches CircularBlue™: A Groundbreaking Marine Debris Cleanup Initiative
TAIPEI, June 12, 2025 /PRNewswire/ -- RHINOSHIELD, the global leader in sustainable phone accessories, proudly announces the launch of CircularBlue™, a pioneering marine debris cleanup initiative designed to combat ocean pollution. As part of RHINOSHIELD's broader sustainability platform, this initiative reinforces the brand's commitment to creating a circular, waste-free future through innovation, design and environmental stewardship. Each year, more than 12.7 million tons of plastic enters our waters, endangering marine life, coral reefs and the global food chain. Alarmingly, 80% of floating waste washes ashore within a month, often in coastal areas neglected by conventional cleanups. CircularBlue™ is RHINOSHIELD's bold response: a scalable, low-energy system designed to target these high-impact zones and drive long-term environmental change. According to Eric Wang, RHINOSHIELD co-founder and CEO, "Plastic pollution is the heavy legacy left by decades of human neglect and abuse. Through CircularBlue™, we are facing this challenge head-on — from coasts to rivers — using bold innovation and scalable solutions to clean up the past and protect the ocean's future." Anchored up to 3 kilometers (approximately 1.86 miles) offshore, the CircularBlue™ platform is a modular, autonomous, three-part system composed of: Solar-powered Floating Platforms that passively collect debris using water jet propulsion based on Bernoulli's principle AI-enabled Scout Drones that detect and signal the location of waste GPS-guided Surface Vessels that retrieve debris in active collection mode The platform's autonomous, energy-efficient design allows for continuous operation in high-waste coastal zones and includes onboard labs for water-quality testing, ecological research and environmental education. Technology Meets Circular Thinking: True to RHINOSHIELD's circular-design philosophy, the plastics collected through CircularBlue™ will be reintegrated into the company's manufacturing cycle — transforming waste into durable, recyclable consumer products and supporting broader circular-economy goals. Built to Scale: From Experimental Project to Global Solution: The platform's prototype — named ChangeMaker Wave Breaker — was developed over 18 months, with an initial hardware investment exceeding $2 million. It reflects RHINOSHIELD's transformation from an accessory manufacturer to a materials-technology lab and, now, a pioneer in marine waste management solutions. Using a blend of fluid dynamics, solar energy and automated collection, the system showcases how industrial design and sustainability can merge to tackle one of the planet's most pressing environmental challenges. It also aligns with RHINOSHIELD's ambition to transform cleaned marine waste into resources, contributing to a truly circular economy. Sustainability at RHINOSHIELD's core: CircularBlue™ extends RHINOSHIELD's longstanding commitment to reducing environmental impact, including: CircularNext: Taiwan's first fully circular phone case, made from recycled SolidSuit phone-case materials RHINOLOOP: A closed-loop program enabling product reuse and recycling Sustainable packaging: Eliminating more than 56 tons of single-use plastic annually and replacing it with FSC-certified paper and vegetable-based inks From product materials to large-scale marine interventions, RHINOSHIELD redefines sustainability by engineering solutions that are both physically resilient and environmentally responsible. "Like our journey over the past 12 years, CircularBlue™ is built on creativity, resilience and a belief that sustainability can be both bold and collaborative," added Wang. "Together with partners around the world, we can restore the ocean we all cherish." RHINOSHIELD invites environmental organizations and technology leaders to collaborate on expanding this platform globally — to restore ocean health, protect biodiversity and reshape the future of sustainable innovation. For more information on RHINOSHIELD and the brand's sustainability efforts, please visit About RHINOSHIELDRHINOSHIELD is a device-accessories brand with evolution at its heart. Since its inception in 2012, the Taiwanese materials-technology company has evolved from startup status into a world-renowned impact-protection accessories brand, pushing ever forward by developing innovative solutions while adhering to a foundational pledge of sustainability. At RHINOSHIELD, we pride ourselves on "Protect Your World." With our focus on reducing environmental impact and plastic waste, what sets RHINOSHIELD apart from the competition is our commitment to mono-material. The 2017 Changemaker campaign marked Rhinoshield's announcement to begin using mono-materials — a commitment to sustainability that prioritizes recyclability without compromising protection, by engineering with the right materials to create meaningful impact. To learn more about our story and initiatives, please visit the official website at ALL MEDIA INQUIRIES AND REQUESTSJustina Rapala Nielsen | FORTE MAREjustina@ View original content to download multimedia: SOURCE Rhinoshield Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
